We dosed the first patients in our Phase 3 program for tilrekimig, an investigational trispecific antibody discovered in @Pfizer laboratories, just months after the encouraging Phase 2 results shared earlier this year.
These three studies are the latest of many pivotal starts in an ambitious year for our R&D portfolio. A fourth Phase 2/3 study in COPD is also ongoing.
Thank you to my colleagues working at great speed on this program and to the patients and families now enrolling. I look forward to sharing more soon.
We’re building Copilot as a new OS for work that spans every model, every form factor, and every task. Today, we’re announcing our biggest update to Copilot to date, bringing four things together:
· Autopilot: proactive and long-running agent built for the enterprise
· Code: build apps with Copilot, hosted inside your company’s tenant
· Home: Chat + Cowork together
· Office: now fully embedded in Copilot (and Copilot embedded in Office, of course!)
Plus, you can invoke Copilot in Teams, and we’re introducing Today, a proactive experience that surfaces the most important information from across M365 without needing to ask for it.
The way we work is changing and so are our workflows. This update brings AI into that flow, from answering a question, to building an app, to getting work done on your behalf.